You are here: Home
Miriam Erlacher Profile Page
Miriam Erlacher

Contact

Lab: Dr. Miriam Erlacher
Department: Pediatrics and Adolescent Medicine
University Medical Center
Address: Div. of Pediatric Hematology and Oncology
Mathildenstr. 1
79106 Freiburg
Phone: 0049 761 270 43010
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Lab homepage: www.frias.uni-freiburg.de/en/people/present-fellows/erlacher
PhD positions available: YES
Research Area: Molecular Medicine
Research Interests: apoptosis signaling; haematopoietic stem cell biology; bone marrow failure; myelodysplastic syndromes; leukemia; stem cell transplantation

CV

Education & Training: 1997-2003 Study of Medicine, University of Innsbruck, Austria
2000-2002 MD thesis, Institute of Experimental Pathophysiology and Immunology, University of Innsbruck, Austria
2003-2006 PhD studies in the program „Molecular Oncology“ at the Innsbruck Medical University, Austria
Employment & Experience: 2003-2006 Postgraduate research fellow in the Division of Developmental Immunology, Medical University Innsbruck
2006 Internship („Tirocinio“) at the Hospital of Sterzing (Italy)
since 07/06 Resident at the Department of Pediatrics and Adolescent Medicine
since 05/09 Fellowship holder within the “Margarete-von-Wrangell Habilitationsprogramm”
(Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg and European Social Fund (ESF))
Scientific Activities: Founding board member of the “Center for Junior Researchers – SciNet”, University of Freiburg, responsible for finances (since 2012)

Honors

Honors and Awards:

ERC starting grant (ApoptoMDS, 2014)

Fellowship for the workshop “Translational Research Training in Hematology”, awarded by the European Hematology Association (EHA) and the American Society for Hematology (ASH), 2010

Fellowship „Margarete von Wrangell-Habilitationsprogramm”, awarded by the Ministerium für Wissenschaft, Forschung und Kunst in Baden-Württemberg and the European Social Fund (May 2009 – April 2013)

Thesis award of the Austrian Society of Allergology and Immunology for the PhD thesis, 2006

Sanofi-Aventis-Award 2006 of the Innsbruck Medical University, October 2006, for the publication “The BH3-only proteins PUMA/bbc3 and Bim are rate-limiting for γ-radiation and glucocorticoid induced apoptosis of lymphoid cells in vivo“ [Blood, 2005]

Poster awards at the ESH Conference Mechanisms of Cell Death and Disease (Cascais, 2008) and at 3th Swiss Apoptosis Meeting (Bern, 2004)

Publications

Selected Publications:

Labi V*, Bertele D*, Woess C, Tischner D, Bock FJ, Schwemmers S, Pahl HL, Geley S, Kunze M, Niemeyer CM, Villunger AV and Erlacher M. Haematopoietic Stem Cell Survival and Transplantation Efficacy is Limited by the BH3-only Proteins Bim and Bmf. EMBO Mol. Med., in press, 2012. Abstract

Labi V, Erlacher M, Krumschnabel G, Manzl C, Tzankov A, Pinon J, Egle A, Villunger A.
Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation.
Genes Dev. 2010 Aug 1;24(15):1602-7. Abstract

Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Sakamoto KM, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M, Starý J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML.Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet. 2010 Aug 8. Abstract

Fritsch A, Loeckermann S, Kern JS, Braun A, Bösl MR, Bley T, Schumann H, von Elverfeldt H, Paul D, Erlacher M, Rautenfeld DB, Hausser I, Fässler R, Bruckner-Tuderman L.  A hypomorphic mouse model for dystrophic epidermolysis bullosa reveals disease mechanisms and responds to fibroblast therapy. J Clin Invest. 2008 May;118(5):1669-79. Abstract

Labi V, Erlacher M, Kiessling S, Manzl S, Frenzel A, O`Reilly LA, Strasser A, Villunger A. Targeted deletion of the BH3-only gene bmf causes defects in B cell homeostasis and accelerates gamma-radiation-induced thymic lymphoma development. J Exp Med. 2008 Mar 17;205(3):641-55.

Erlacher M, Labi V, Böck G, Tzankov A, Strasser A, Villunger A. Combined loss of Bim and Puma mirrors the effects of Bcl-2 overexpression in some but not all forms of cell death. J Exp Med. 2006 Dec 25;203(13):2939-51.

Teis D, Kurzbauer R, Hilber D, Erlacher M, Villunger A, Geley S, Bohn G, Klein K, Hess M,  Huber LA. The p14/MP1-scaffold complex is required for endosomal ERK activation and cell cycle progression in vivo. J Cell Biol. 2006 Dec 18;175(6):861-8. Abstract

You H, Pellegrini M, Tsuchihara K, Yamamoto K, Hacker G, Erlacher M, Villunger A, Mak TW. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med. 2006 Jul 10;203(7):1657-63. Epub 2006 Jun 26. Abstract

Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L, Adams JM,
Strasser A, Villunger A. The BH3-only proteins PUMA/bbc3 and Bim are rate-limiting for γ-radiation and glucocorticoid induced apoptosis of lymphoid cells in vivo. Blood. 2005 Aug 23; 2005 Dec 15;106(13):4131-8. Abstract

Erlacher M, Knoflach M, Stec IE, Böck G, Wick G, Wiegers GJ. TCR signaling inhibits glucocorticoid-induced apoptosis in murine thymocytes depending on the stage of development. Eur J Immunol.  2005 Nov;35(11):3287-96. Abstract

 

SGBM PhD students

SGBM PhD students:

Track 2:

Christian Molnar (since March 2015)

Copyright © 2009-2018 University of Freiburg